Estrogen receptor alpha (ERa) is a critical player in development and function of the female reproductive system. Perturbations in ERa response can affect wide-ranging aspects of health in humans as well as in livestock and wildlife. Because of its long-known and broad impact, ERa mechanisms of action continue to be the focus on cutting-edge research efforts. Consequently, novel insights have greatly advanced understanding of every aspect of estrogen signaling. In this review, we attempt to briefly outline the current understanding of ERa mediated mechanisms in the context of the female reproductive system.
Estrogen receptor
The vast majority of estrogen's activities are mediated by the estrogen receptor (ER), a member of the nuclear receptor family of hormone activated transcription factors. Our understanding of the physiological role of estrogen action has been greatly advanced by the generation of experimental mouse and rat models with knockout of receptors or coactivators either globally or in specific tissues and cells, or with knock-in expression of mutated forms of these molecules. These models, used in combination with microarray, RNA next generation sequencing (RNA-seq), and chromatin immunoprecipitation next generation sequencing (ChIP-seq) methods, allow comprehensive mapping of interaction of ERs with the chromatin landscape to impact genomic response. Together, these models and techniques have led to better understanding of the molecular details of ER roles in biological processes.
Estrogen receptor alpha (ERa) cDNA was the first described and cloned estrogen receptor (termed ESR1 (ERa)) (Walter et al. 1985) . A second ER gene, termed ESR2 (ERb), was discovered in 1996 (Kuiper et al. 1996) . ERa and ERb are not isoforms but rather distinct receptors encoded by two separate genes on different chromosomes. ERa is found on chromosome 6 in humans and chromosome 10 in mice. ERb is found on chromosome 14 in humans and chromosome 12 in mice. The ERa proteins are 595 and 599 amino acids in length in humans and mice respectively with an approximate molecular weight of 66 kDa ( Fig. 1) (Heldring et al. 2007 , Le Romancer et al. 2011 , Gibson & Saunders 2012 .
The ESR2 encodes a receptor of 549 amino acids in rodents and 530 amino acids in humans, each with an approximate molecular weight of 60-63 kDa ( Fig. 1 ) (Gibson & Saunders 2012) . Therefore, ERb is slightly smaller than ERa, and most of these differences lie within the smaller N-terminus.
Receptor structure
The estrogen receptors are composed of five functional domains ( Fig. 1) , an N-terminal domain (NTD) or A/B domain, the DNA-binding (DBD or C) domain, a hinge (D) region, LBD (LBD or E), and a C-terminal F domain (Laudet & Gronemeyer 2001 , Aagaard et al. 2011 , Hilser & Thompson 2011 , Brelivet et al. 2012 , Helsen et al. 2012 .
NTD or A/B domain
Crystallography of the ER NTD or A/B domain has been largely unsuccessful because this portion of the receptor is unstructured and fluctuates in aqueous solutions. However, evidence suggests that intramolecular interactions between the A/B and other receptor domains are likely to induce a more structured NTD (McEwan 2004 , Aagaard et al. 2011 , Hilser & Thompson 2011 , as evidenced from recent cryogenic Electron Microscopy (cryo-EM) studies (Yi et al. 2015) . Current models of ER signaling incorporate the flexibility of intrinsically disordered (ID) regions of the receptor, including the NTD, into a mechanism of allosteric interaction and coordination of ligand, DNA motif and ER domain functions (Aagaard et al. 2011 , Hilser & Thompson 2011 . The NTD contains the transcriptional activation function-1 (AF-1) domain and provides for cell-and promoter-specific activity of the receptor as well as a site for interaction with coreceptor proteins (Table 1) . More recent description of full-length ERa structure derived using cryo-EM indicates A/B domain is positioned near the LBD and facilitates recruitment of the steroid receptor transcriptional coactivator, SRC-3 (Yi et al. 2015) . Posttranslational modifications, such as phosphorylation, of the A/B domain can dramatically affect the overall behavior of the receptor and are thought to be an important mechanism for the modulation of AF-1 functions (Le Romancer et al. 2011 ).
DNA-binding or C domain
The C domain of the ER recognizes and binds to the cisacting enhancer sequences, called estrogen responsive elements (EREs) (Helsen et al. 2012 ). The C domain contains two zinc fingers, each composed of four cysteine residues that chelate a single Zn 2 ion. Crystallography studies indicate a highly conserved structure consisting of dual a-helices positioned perpendicular to each other (Aagaard et al. 2011 , Hilser & Thompson 2011 , Helsen et al. 2012 . Amino acids in the C-terminal 'knuckle' of the first zinc finger form the proximal box ('P-box') of the DNA binding domain and confer DNA sequence recognition specificity to the receptor for binding DNA sequences; hence, the proximal zinc finger is often referred as forming the 'recognition helix. ' Amino acids at the N-terminal 'knuckle' of the second zinc finger form the distal box ('D-box') and are more specifically involved in differentiating the 'spacer' sequence within the ERE as well as providing a secondary interface for receptor dimerization. The consensus motif (ERE) that ER binds is composed of a six-base pair (bp) palindromic sequence arranged as an inverted repeat and separated by a three-bp spacer, GGTCAnnnTGACC. The inverted-repeat arrangement of the ERE dictates that the ER homodimerizes in a 'headto-head' position when bound to DNA. Structural analysis has revealed the importance of the 10-30 amino acid carboxy terminal extension (CTE) of the DBD in DNA interaction (Aagaard et al. 2011 , Hilser & Thompson 2011 , Helsen et al. 2012 . Although this CTE region is variable between steroid receptors, it is crucial for DNA binding, particularly for sequence selectivity of DNA binding, by extending the interaction surfaces between the receptor and the DNA.
Hinge region or D domain
The above described CTE extends into the hinge region, which also contains a nuclear localization signal, and influences cellular compartmentalization of ER, as well as sites of post-translation modifications (Kim et al. 2006) . Current mechanisms suggest this non-conserved and ID domain is important for intra-molecular allosteric interactions involving the N-terminal and LBD. This type of flexible structural interaction works to allow rapid response to diverse modulators governing changes in biological environments (Kumar & McEwan 2012) .
LBD or E domain
The LBD or E domain of the ER is a highly structured multifunctional region that primarily serves to specifically bind estrogen and provide for hormone-dependent transcriptional activity through an activation function 2 (AF-2) domain located close to the C-terminus of the E domain. A strong receptor dimerization interface, sites for interaction with heat shock proteins, and nuclear localization signals are also within the E domain (Laudet & Gronemeyer 2001 , Kumar & McEwan 2012 . Structural studies indicate that the LBD is composed of 11 a-helices (H1, and H3 through H12) arranged in a three-layer a-helical sandwich to create a hydrophobic ligand-binding pocket near the C-terminus of the receptor (Huang et al. 2010) . Receptor binding to an estrogen agonist leads to rearrangement of the LBD such that H11 is repositioned and H12 rotates back toward the core of the domain to form a 'lid' over the binding pocket. This agonist-induced repositioning of H12 leads to the formation of a hydrophobic cleft, or 'NR box,' by helices 3, 4, and 5 on the receptor surface, constituting the AF-2, which serves to recruit coactivators (Table 1) to the receptor complex.
In contrast, estrogen antagonists are unable to induce a similar repositioning of H12, leading to a receptor formation that is incompatible with coactivator recruitment and is therefore less likely to activate transcription. The LBDs of ERa and ERb exhibit w60% homology ( Fig. 1 ) but bind the endogenous estrogen, estradiol (E 2 ), with similar affinity (ERa, 0.1 nM; ERb, 0.4 nM) (Le Romancer et al. 2011 , Gibson & Saunders 2012 indicating only a small portion of the LBD sequence governs the specificity of ligand binding. However, given the divergence in homology, it is not surprising that ERa and ERb exhibit measurable differences in their affinity for other endogenous steroids and xenoestrogens (Le Romancer et al. 2011 , Gibson & Saunders 2012 . Natural and synthetic steroidal and non-steroidal ER agonists and antagonists have been described, some of which show specificity or preference for one or the other ER subtype, illustrating differences between the LBDs of ERa and ERb and provide for conceptual pharmacological tools to discern the overall function of each ER. The most widely used ER sub-type selective ligands currently in use are propylpyrazole (PPT), an ERa selective agonist, and diarylpropionitrate (DPN), an agonist showing preference, but not exclusive selectivity, towards ERb (Stauffer et al. 2000 , Meyers et al. 2001 .
F domain
Among the sex steroid receptors, only ERs possess a welldefined F domain (Fig. 1 ). This region is relatively unstructured with little known function, although some data indicate a role in coactivator recruitment, dimerization and receptor stability , Koide et al. 2007 , Yang et al. 2008 , Kumar et al. 2011 , Arao et al. 2013 .
Coregulatory complexes
All steroid receptors interact with coregulatory molecules, coactivators, and corepressors (Hsia et al. 2010 , George et al. 2011 
Mechanisms of estrogen response
Our understanding of the mechanisms by which estrogens influence cell function and behavior has expanded profoundly since initial models of ligand-dependent activation, which is now referred to as the 'classical' or ligand dependent direct DNA binding model of receptor function (Fig. 2) . In the years since, numerous discoveries primarily in cell-based systems have been made that illuminate the complexity of ER signaling in cells and tissues. The entrée into the 'omics' era has facilitated massive expansion for the study of transcriptional regulation and chromatin remodeling. In addition, several alternative receptor signaling mechanisms that diverge from the classic model have become apparent, including 'tethering' of the ER to heterologous DNA-bound transcription factors to provide for regulation of genes that lack ERE sequences (Fig. 2) ; plasma membrane estrogen signaling, often referred to as 'nongenomic' steroid actions and ligand-independent 'cross-talk' with intracellular and second messenger systems that provide for ER activation in the absence of the cognate steroid ligand (Fig. 2) . These modes of ER responses as currently understood are discussed below.
Ligand-dependent actions: direct or classical
In the classic model of estrogen response (Figs 2 and 3) estrogen ligands diffuse across the plasma and nuclear membranes to bind ER, primarily localized to the nucleus, resulting in a conformational change in the receptor, transforming it to an 'activated' state that interacts with chromatin via ERE motifs and transcriptional mediators. ERs seem to be preferentially recruited to open regions of chromatin (Biddie et al. 2010) . Studies using MCF7 breast cancer cells indicate that FoxA1 acts as a pioneering factor, providing accessible regions in the chromatin that recruit ERa ( Fig. 3 ) (Carroll et al. 2005 , Carroll & Brown 2006 , Fu et al. 2011 , Zaret & Carroll 2011 . The ligand-ERE-bound receptor complex then engages coactivator molecules as described above (Johnson & O'Malley 2012) leading to modulation of transcription rates of responding genes. This classic steroid receptor mechanism is dependent on the functions of both AF-1 and AF-2 domains of the receptor, which synergize via the recruitment of coactivator proteins, most notably the p160 family members (Johnson & O'Malley 2012) . Depending on the cell and target gene promoter context, the DNA-bound receptor complex may positively or negatively affect expression of the downstream target gene. Initially, study of ER mediated gene regulation was carried out on a gene-by gene basis using a handful of known hormone regulated transcripts. Now, after numerous comprehensive analyses of hormonally regulated transcriptional profiles, using microarray and more recently RNA-seq, thousands of ER targets have been found in various cell lines and tissues.
Indirect/tethered actions (ERE independent)
In in vitro reporter gene systems, ligand-activated ER can modulate the expression of genes that lack a conspicuous ERE within their promoter (Kushner et al. 2000 , Safe & Kim 2004 . This mechanism of ERE-independent steroid receptor activation is postulated to involve a 'tethering' of the ligand-activated receptor to transcription factors that are directly bound to DNA via their respective response elements ( Fig. 2) . However, the ERa EAAE/EAAE mouse, which is mutated in the ERa DBD and lacks ERE binding, does not exhibit estrogen response in vivo, indicating the tethering mechanism, at least on its own, is unable to mediate hormonal responses (Ahlbory-Dieker et al. 2009 and is likely complimentary to the direct DNA stimulated responses.
Non-genomic actions
Rapid effects of E 2 have been described, including a rapid activation of endothelial nitric oxide synthase in endothelial cells (Levin 2011 ) and potentiation of nerve conductance (Takeo & Sakuma 1995 , Kim et al. 2011a .
Because these estrogen effects occur within minutes, they have been thought not to involve direct ER activation of gene transcription, they are often collectively referred to as representing 'non-genomic' pathways of estrogen action. Questions remain concerning whether the membrane-associated receptors mediating these events are identical or variant forms of the ER or instead distinct receptors altogether. One potential mediator of rapid membrane localized hormone response is the G protein coupled ER (GPER, originally referred to as GPR30), which is activated by E 2 (Prossnitz & Barton 2011) . Gper null mice lack reproductive phenotypes (Langer et al. 2010) , although effects on the degrees of uterine responses elicited by E 2 have been Ligand-dependent and ligand-independent nuclear receptor mechanisms. The direct 'classic' model of ER action involves direct interaction between ER bound to estrogen (triangles) and ERE; the tethered pathway utilizes indirect 'tethering' of ER to genes via interactions with other transcription factors (TF). 'Nongenomic' signaling is initiated by membrane-localized receptors modulating extranuclear second messenger (SM) signaling pathways. Ligand-independent responses occur as a result of transduction observed with G15, a GPER selective antagonist, suggesting a potential role for GPER in modulating ERa mediated responsiveness .
Ligand independent actions: membrane receptor cross-talk
Peptide growth factors are able to activate ERa-mediated gene expression via mitogen-activated protein kinase activation of ERa in the absence of E 2 (Fig. 2) . Likewise, growth factors are able to mimic the effects of E 2 in the rodent uterus via E 2 independent activation of ERa , Fox et al. 2009 ). In some cases, the MAP kinase protein ERK is corecruited to chromatin with ERa (Madak-Erdogan et al. 2011). Ligand-independent activation of estrogen receptors is believed to rely largely on cellular kinase pathways that alter the phosphorylation state of the receptor and/or its associated proteins (e.g., coactivators, heat shock proteins) (Fig. 2) .
Uterine response to E 2
Utilizing animal models to follow and manipulate estrogen responsiveness is one way to understand and describe mechanisms of estrogen responses. The reproductive function of the mouse has been especially well studied and characterized in this manner.
Treatment of ovariectomized mice with estrogens (e.g., E 2 or diethylstilbestrol -DES) has long served as an experimental model to mimic the uterine events that occur during the estrous phase of the rodent cycle or immediately after the preovulatory E 2 surge. Morphological and biochemical changes occur in the rodent uterus after estrogen stimulation following an established biphasic temporal pattern (Hewitt et al. 2003) . Estrogenstimulated changes in the rodent uterus that occur early, within the first 6 h after treatment, include increases in nuclear ER occupancy, water imbibition, vascular permeability and hyperemia, prostaglandin release, glucose metabolism, eosinophil infiltration, gene expression (e.g., c-fos), lipid and protein synthesis. ERa ChIP-Seq profiles from in vivo studies of uterine tissues show that in the unstimulated state the receptor pre-occupies chromatin sites in the absence of hormone and that E 2 treatment increases ERa recruitment (Hewitt et al. 2012) . The above processes are followed by responses that peak after 24-72 h and include dramatic increases in RNA and DNA synthesis, epithelial proliferation, and differentiation of epithelial cells toward a more columnar secretory phenotype, dramatic increases in uterine weight, and continued gene expression.
Changes in uterine gene expression
The dramatic physiological changes that occur in the uterus in response to steroid hormones are presumably the ultimate effects of equally dramatic changes in gene expression among the uterine cells. It is unlikely that the E 2 -ER complex is directly involved in mediating the whole genomic response in the uterus but more plausibly serves to stimulate a cascade of downstream signaling pathways that act to amplify the estrogen action. However, early investigations of the genomic response to estrogens in the rodent uterus discovered a handful of genes that are directly regulated via the classic ER mode of action, including progesterone receptor (Pgr) and lactoferrin or lactotransferrin (Ltf). Microarray analysis has significantly advanced understanding of genomic response of the rodent uterus to E 2 . Numerous studies have used microarray techniques to map the global gene expression patterns after estrogen exposure in the uterus and largely demonstrate that the biphasic uterine response to estrogens, so well characterized by physiological indicators above, is mirrored by the global changes in gene expression (Andrade et al. 2002 , Fertuck et al. 2003 , Hewitt et al. 2003 , Watanabe et al. 2003 , Ho Hong et al. 2004 , Moggs et al. 2004 , Hewitt et al. 2005 , Hong et al. 2006 . The clearly defined patterns of early and late response genes found in mouse uterine tissues are completely lacking in ERa-null (aERKO, Ex3aERKO) uteri (Hewitt et al. 2003 (Hewitt et al. , 2010a . The identified genes fall into functional groups, including signal transduction, gene transcription, metabolism, protein synthesis and processing, immune function, and cell cycle. The expression levels of a striking number of genes are actively repressed by estrogen in the mouse uterus, and these effects were absent in ERa-null uteri or are relieved by cotreatment with ER antagonists in the presence of ERa, indicating that ERa is also actively involved in transcriptional repression as part of mediating the physiological responses (Hewitt et al. 2003 (Hewitt et al. , 2010a .
Whole transcriptome analyses are now routinely incorporated into studies of disruptions in signaling pathways underlying uterine phenotypes of mouse models such as those described in Table 2 . Thus, microarray comparisons have now become just one of many tools employed for investigation of uterine functions.
Chip-seq
Evaluation of sites of transcription factor interaction with chromatin, by enriching a DNA binding protein, such as ERa, that has been crosslinked in situ to chromatin, with immunoprecipitation (ChIP), followed by hybridizing the associated DNA to a chip tiled with promoter region sequences (ChIP-Chip) or by 'next generation' massively parallel sequencing (ChIP-seq), have been developed and widely utilized to study sites of ER interaction (Farnham 2009 , Park 2009 , Biddie et al. 2010 , Green & Han 2011 , Martens et al. 2011 , Meyer et al. 2012 . Initial studies focused on ERa binding in MCF7 breast cancer cells, and several similar studies followed, which are summarized and compared in several review articles (Deblois & Giguere 2008 , Cheung & Kraus 2010 , Gao & Dahlman-Wright 2011 , Tang et al. 2011 , Gilfillan et al. 2012 . These articles reported that most sites were distal from transcriptional start sites (TSS), or were in intronic regions, rather than adjacent to TSS, as models of ER regulation of target transcripts had hypothesized. These comprehensive maps of cis-acting transcriptional regulators have been dubbed 'cistromes.' The initial ERa cistrome-associated sequences were evaluated for enrichment of transcription factor motifs and confirmed binding to the experimentally defined 'ERE' sequence. In the case of the MCF7 tumor cells, enrichment of motifs for forkhead binding factors (Fox) was apparent as mentioned in the earlier section. Owing to the abundant expression of the FoxA1 member of the Fox family, a potential role for FoxA1 in estrogen response was pursued with an arsenal of bioinformatic, Next Gen sequencing and biological studies that demonstrated FoxA1's role as 'pioneer,' creating accessible regions of the chromatin that were subsequently targeted by ERa (Lupien et al. 2009 , Zaret & Carroll 2011 .
ChIP-seq analysis is examining the ERa binding sites in mouse uterine tissue indicated that, much like the MCF7 breast cancer study, most ERa sites were not proximal to TSS (Hewitt et al. 2012) . ERs bind to thousands of sites within the cellular chromatin, and not all potential EREs in every cell bind ER. Rather, it is apparent that chromatin exhibits 'pre-opened' regions destined to recruit ER (Grontved & Hager 2012) . For ER in MCF7 and FoxA1 can establish ER accessible regions. The accessible chromatin regions are colocalized within nuclear 'hubs,' which seem to optimize frequency of interaction with ER (Grontved & Hager 2012) . ChIP-seq is also used to locate other molecules involved in chromatin remodeling and transcriptional regulation, and to examine activating or repressive histone modifications or 'marks.' These maps of relative locations and dynamics of ER and chromatin components greatly enhance our understanding of hormone response mechanisms (Deblois & Giguere 2008 , Green & Han 2011 , Martens et al. 2011 , Gilfillan et al. 2012 , Meyer et al. 2012 .
Uterine phenotypes in mouse models of disrupted estrogen signaling
Mouse models of disrupted ER signaling have proven invaluable to experimental investigation of estrogen actions and the contribution of each ER form to these functions (Table 2 ). In addition to the ER-null models are lines of mice that lack the capacity to synthesize E 2 due to disruption of the Cyp19 gene (Fisher et al. 1998 , Toda et al. 2001 . Below we will describe how these different mouse models have helped to delineate the biological role of ER mechanisms in estrogen hormone action.
ERa null patients and mice
Only one male patient and one female patient with ERa mutation have been described (Smith et al. 1994 , Quaynor et al. 2013 . The male patient's mutation is a true null since no ERa protein is expressed due to the mutation generating a premature stop codon in the A/B domain. The female patient has a single point mutation in her ERa LBD that results in decreased activity by reducing the receptors affinity for coactivator proteins more than 200-fold. There are currently numerous reported lines of ERanull mice and additional lines of mice with mutations in functional domains of ERa. Three separate lines of ERanull mice were generated: the aERKO, first described by Lubahn et al. (1993) , the ERaKO (or Ex3aERKO), described by Dupont et al. (2000) and by Hewitt et al. (2010a,b) , and ERa K/K described by Antonson et al. (2012) . Homologous recombination was employed to disrupt ERa (aERKO), or cre-mediated recombination was used to completely excise exon 3, which encodes the ER DNA binding domain (Dupont et al. 2000 , Hewitt et al. 2010a ,b, Antonson et al. 2012 of the murine Esr1 (ERa) gene (ERaKO, Ex3aERKO, and ERa K/K ). The uterine estrogenic response in aERKO females differs from the latter two lines, but the overall spectrum of phenotypes are the same, as aERKO animals have minimal level of truncated ERa protein produced from a splice variant, which preserves some residual biological functions (Couse et al. 1995) , but all ERa null female mice are infertile. Recently, an ERa null rat has been derived using zinc finger nuclease (ZFN) genome editing. All phenotypes in the ERa null rats examined thus far were previously seen in the ERa null mice, including infertility due to hypoplastic uteri, polycystic ovaries, and ovulation defects (Rumi et al. 2014) . The female patient with homozygous ERa mutation also has cystic ovaries and a small uterus despite elevated circulating serum E 2 (Quaynor et al. 2013) .
The essential role of ERa in uterine response to estrogen is indicated by the loss of early phase effects of water imbibition and hyperemia as well as the late-phase effects of increased DNA synthesis and epithelial proliferation in ERa-null uteri (Couse et al. 1995 , Korach et al. 1996 , Hewitt et al. 2010a . The aERKO model was the first test of a prevailing hypothesis that early uterine effects were non-receptor mediated (Lubahn et al. 1993) . Lack of these early responses of water imbibition, hyperemia, and eosinophil infiltration in aERKO indicated that ERa was involved in some manner and these responses clearly require the estrogen receptor. Additionally, ovariectomized mice normally exhibit a three-to four-fold increase in uterine weight after three daily treatments with E 2 or DES, whereas no such response is observed in the uteri of ERa-null females (Lubahn et al. 1993 , Korach 1994 , Hewitt et al. 2010a . Uteri of mice that lack ERa just in uterine epithelial cells (Wnt7a
Epi-cKO) have an initial proliferative response to estrogen, but full uterine response is impaired, as the growth after 3 days of estrogen treatment is significantly less than expected (Winuthayanon et al. 2010) . The total lack of response to estrogens in ERa-null uteri as well as a lack of late biological response in epithelial ERa knockout uteri provide strong evidence that ERa is required to mediate the full biochemical and biological uterine response to estrogens (Hewitt et al. 2010a ,b, Winuthayanon et al. 2010 . Numerous studies have demonstrated some of the molecular mechanisms of E 2 -induced uterine epithelial cell proliferative responses in animal models. The transcription factor CCAAT enhancer binding protein beta (C/EBPb) is involved in hormone-induced uterine proliferation (Mantena et al. 2006) . Maximum uterine expression of C/EBPb is induced 1 h after E 2 treatment in both epithelial and stromal cells (Mantena et al. 2006 , Ramathal et al. 2010 . ICI 182,786 (ER antagonist) strongly inhibited E 2 -induced Cebpb transcript in the uterus suggesting an ER-dependent expression of C/EBPb (Bagchi et al. 2006) . In addition, loss of epithelial ERa in the uterus did not alter E 2 -induced Cebpb expression, indicating that Cebpb expression is independent of epithelial ER (Winuthayanon et al. 2010) , and suggesting the stimulation was through a paracrine mechanism via stromal ERa. This points to the action of estrogen through ERa as the major mediator of C/EBPb expression in the uterus. Indeed, the deletion of C/EBPb (C/EBPb K/K ) leads to a lack of the E-induced uterine proliferative response (Mantena et al. 2006) as reflected by the absence of mitotic activity, S-phase activity and an increase in apoptotic activity in the uterine epithelial cells (Ramathal et al. 2010) . In addition to a blunted uterine growth response to hormones, the C/EBPb K/K females also exhibit complete infertility (Bagchi et al. 2006) , due to implantation and decidualization defects (Mantena et al. 2006) . Pan et al. (2006) demonstrated that the uterine expression of minichromosome maintenance proteins (MCMs), a complex required for DNA synthesis initiation, is induced after E 2 treatment, specifically MCM2 and MCM3. MCM2 activity is crucial and required for DNA synthesis in uterine epithelial cells (Ray & Pollard 2012) . Further study demonstrated E 2 -mediated induction of the transcription factor KLF4, which then targets the Mcm2 promoter (Ray & Pollard 2012) .
Mice lacking ERb
ERb-null mice have provided insight into the importance of ERb to female fertility and studies to date indicate ERb plays a particularly important role in ovarian function. Four different lines of ERb-null mice have been described. The bERKO mouse, made using homologous recombination was first described by Krege et al. (1998) , and the ERbKO or Ex3bERKO, was described by Dupont et al. (2000) , and by Binder et al. (2013) . Cre-mediated recombination was employed in both lines to disrupt exon 3 (Dupont et al. 2000 , Binder et al. 2013 ) of the murine Esr2 (ERb) gene. As described to date, the reproductive, endocrine, and ovarian phenotypes of both lines are indistinguishable, with both exhibiting female subfertility. Shughrue et al. (2002) reported the third line of ERbKO animals, however, no uterine or ovarian phenotypes were reported (Shughrue et al. 2002) . Recently, ERbKO ST LK/LK animals, which contain LoxP sites flanking exon 3 of Esr2, were generated using the Cre/loxP recombination system (Antal et al. 2008) . Interestingly, female mice from this recently described ERbKO ST LK/LK colony were reported to be sterile due to an ovarian defect while Ex3bERKO (Binder et al. 2013 ) are subfertile, due to ovulatory defects.
Mice lacking ER a and b
The two reported lines of compound ER-null mice are the abERKO, described by , and the ERabKO, described by Dupont et al. (2000) . Both were generated by cross breeding animals heterozygous for the respective individual ER-null mice and as described to date, exhibit comparable reproductive, endocrine, and ovarian phenotypes. The most striking phenotype is the unique trans-differentiation of the ovarian granulosa cells to sertoli-like cells in follicles of abERKO females which is age dependent. To date, no manipulation of the individual aERKO or bERKO mouse lines can reproduce this novel phenotype. This model clearly uncovered that both ER signaling systems are required to maintain the proper differentiation state of the adult granulosa cells.
Mice lacking Cyp19
Estrogens are produced by aromatase cytochrome P450, the product of Cyp19 gene. Female mice with disruption of circulating estrogen production exhibit altered reproduction (Fisher et al. 1998 , Honda et al. 1998 , Toda et al. 2001 ).
There are three animal models of Cyp19-null mice (called ArKO). Fisher et al. (1998) reported the first mouse line in 1998, which disrupted exon 9 of Cyp19 gene, as the region is highly conserved. Later, Honda et al. (1998) reported a mouse line with targeted disruption of exons 1 and 2 of the Cyp19 gene. Subsequently, Toda et al. (2001) generated the most recent mouse line of Cyp19-null in 2001 with a targeted disruption of exon 9 of the Cyp19 gene. These ArKO female phenotypes are indistinguishable (Fisher et al. 1998 , Honda et al. 1998 , Toda et al. 2001 , with similarity to the abERKO mice with a clear metabolic syndrome and infertility due to ovarian dysfunction marked by cystic follicles and a failure to respond to exogenous gonadotropins. Interestingly, the phenotype of the original ArKO mice (Fisher et al. 1998) were also shown to exhibit the same age related ovarian phenotype (Britt et al. 2002) as the abERKO mice, indicating that hormone mediated ER action is required.
Female reproductive phenotypes in mice with disrupted estrogen signaling
Females within each respective model exhibit a similar phenotypic syndrome. Female mice lacking ERa or aromatase are infertile due to dysfunction of numerous physiological systems, including the ovary and uterus, whereas ERb-null females exhibit reduction or loss of fecundity that is largely attributable to ovarian dysfunction. A level of caution is warranted when making phenotypic comparisons between the ER-null and Cyp19-null models because sensitivity to maternally derived estrogens may provide a more normal developmental environment during gestation in Cyp19-null mice and sensitivity to dietary estrogens during adulthood is able to abate several phenotypes in Cyp19-null mice (Britt et al. 2002) . The reported uterine phenotypes of these models are summarized in Table 2 . All lines of ER-null females exhibit uteri that possess the expected tissue compartments, myometrium, endometrial stroma, and epithelium , Hewitt et al. 2010a . However, in females lacking functional ERa or Cyp19, uteri are overtly hypoplastic and exhibit severely reduced weights relative to wild-type littermates (Fisher et al. 1998 , Britt et al. 2001 , Toda et al. 2001 , whereas ERb-null uteri are grossly normal and normally responsive to ovarian-derived steroids . The uterus of ERa-null females is severely hypotrophic, poorly organized, and possesses a paucity of glandular structures (Korach et al. 1996 , Hewitt et al. 2010a . The luminal and glandular epithelial cells in ERa-null uteri are severely immature with fewer glands present in the adults (Nanjappa et al. 2015) and consistently exhibit a cuboidal morphology, vs the tall columnar morphology and basal location of the nucleus of an 'estrogenized' epithelium in WT uteri. Therefore, fetal, neonatal, and perinatal development of the female reproductive tract in mice is largely independent of ERa-and ERb-mediated actions, but estrogen responsiveness and sexual maturation of the adult uterus are ablated after the loss of functional ERa. The totality of the ERa-null phenotype and lack of any overt uterine abnormalities in ERb-null females suggest that ERb has little meaningful function in mediating estrogen actions in the uterus. Moreover, ERab-null also demonstrated a similar uterine phenotype as ERa-null (Walker & Korach 2004) . Weihua et al. (2000) reported that ERb-null females exhibited a slightly aberrant uterine growth response after estrogen replacement; however, the uterine bioassay was conducted in immature intact, not ovariectomized adult, animals. In addition, Wada-Hiraike et al. (2006) showed that in immature females, loss of ERb leads to increased uterine epithelial proliferation induced by E 2 compared with WT uteri. Although ERb-null females are subfertile, when pregnancies are established they are sustained to term (Krege et al. 1998) , indicating uterine competence. More recent findings suggest that loss of ERb leads to complete sterility due to a defect in ovarian function (Dupont et al. 2000 , Antal et al. 2008 .
Mice with uterine specific deletion of ERa
Selectively deleting ERa in the uterus postpubertally, using the Cre/LoxP recombination system, by crossing Pgr
CreC with Esr1
f/f animals (Esr1 d/d ), leads to a hypoplastic uterus that lacks a decidual response (Pawar et al. 2015) . Our laboratory has described uterine epithelial cell selective deletion of ERa, using the Cre/LoxP recombination system, by crossing Wnt7a CreC (Huang et al. 2012) with Esr1 f/f animals (Hewitt et al. 2010a,b) (ERa Epi-cKO).
The expression of ERa in the uterine luminal and glandular epithelium of these animals was ablated, while the ERa expression in the stromal cells and other uterine cells remains intact (Winuthayanon et al. 2010) . The epithelial ERa was ablated not only in the uterus in this mouse line (Winuthayanon et al. 2010) , but also in the oviduct . As expected, based on findings in the global ERa knockouts, loss of uterine epithelial ERa has no effect on female reproductive tract development. Uterine histological analysis showed a similar uterine morphology as WT control (Winuthayanon et al. 2010) . The ERa Epi-cKO uteri are sensitive to 24 h treatment of E 2 , as the uterine epithelial proliferation is preserved. However, ERa Epi-cKO uteri lack a complete uterine response to E 2 , following a 3-day uterine bioassay, which demonstrated a blunted growth response and increased apoptotic activity in ERa Epi-cKO compared with the control uteri. Additionally, a lack of ERa expression in the uterine epithelial cells contributes to complete infertility, due to oviduct, and uterine implantation and decidulaization defects (Winuthayanon et al. 2010 , Pawar et al. 2015 . This suggests that uterine epithelial ERa is dispensable for early uterine proliferative responses but crucial for a complete adult biological response induced by E 2 , as well as for establishing pregnancy.
Mice with mutated DNA binding domains of ERa
To date, there are two mouse lines with mutations that are designed to disrupt the DNA binding function of the ERa that have been 'knocked-in' (KI) at the ERa gene locus. The first line was generated by replacing critical P-box amino acids E207 and G208 with alanines (ERa AA ). This line was named 'non-genomic ER knock-in' (NERKI), as these mutations were intended to restrict ERa signaling to the non-genomic and tethered mechanisms. Female NERKI C/K animals that have one mutated allele and one WT allele (Jakacka et al. 2002) were infertile, exhibiting a highly novel hyperplastic uterine phenotype, so NERKI C/K males were crossed with ERa null heterozygous (WT/KO) females to produce mice with one NERKI mutated allele and one deleted Esr1 allele, called ERa KIKO or ERa The NERKI C/K females have normal uterine development but exhibit hyperplastic uteri, and are hypersensitive to estrogen (Jakacka et al. 2002) . These NERKI C/K are infertile and exhibit a uterine abnormality of enlarged hyperplastic endometrial glands despite possessing normal levels of circulating sex steroids. ERa AA/K females have normal uterine development.
Initially, O'Brien et al. (2006) reported that ERa AA/K females, with mutation of the DNA binding domain, maintained proliferative responses induced by E 2 . However, in subsequent studies, no uterine proliferation was observed (Hewitt et al. 2009 (Hewitt et al. , 2010 at all times, whereas, the PR is restricted at times, to epithelial cells and is dynamically induced in the stromal cells during the estrous cycle. Additionally, the phenotype also indicates the specificity of the action at the HRE requires the proper activity of the PR to elicit the dampening action.
Mice with mutated AF-1 or AF-2 domains of ERa
As discussed in the Receptor structure section, AF-1 and AF-2 are important for ER transcriptional activity (Fig. 1 (Sinkevicius et al. 2008 , Billon-Gales et al. 2009 , Billon-Gales et al. 2011 . ERaAF-18 females exhibited minimal uterine wet weight gain compared with ER C/C uteri after treatment with E 2 pellets for two consecutive weeks, while ERaAF-28 females did not respond (Billon-Gales et al. 2009 , 2011 , Abot et al. 2013 . This indicates that the ERa AF-2 functional domain contributes to minimal uterine weight increase induced by E 2 in the absence of AF-1. Both lines of AF-2 mutated animals (ERa G525L and AF2ER KI/KI ) display severely hypoplastic uteri, and lack uterine growth response to E 2 treatment (Sinkevicius et al. 2008 , Billon-Gales et al. 2011 . Interestingly, uterine wet weight can be increased by using the synthetic ERa agonist PPT in ERa G525L or by using the ER antagonists ICI 182,780 or tamoxifen in AF2ER KI/KI females (Sinkevicius et al. 2008 . The ability of the antagonists to mediate responses seems to be due to a unique conformation of the LBD of the AF2ER that leads to AF-1-dependent transcriptional activity (Arao et al. , 2013 . Arao et al. (2011) also demonstrated that the uterine response to ICI or tamoxifen includes increased DNA synthesis in the uterine epithelial cells of AF2ER KI/KI . The growth factor IGF-1 induced minimal uterine epithelial proliferation in ERa G525L , and was not seen in AF2ER KI/KI uteri (Sinkevicius et al. 2008 ).
Together, these findings indicated that both AF-1 and AF-2 activation domains of ERa contribute to a normal regulation of the complete biological response of uterine growth and reproductive functions. As the AF domains mediate ER-coregulator interaction (Table 1) , this emphasizes the importance of effective ERa coactivator protein recruitment for successful uterine E 2 response. Similarly, mice lacking sufficient SRC-1 coactivator (SRC1 K/K ), exhibit measurably diminished uterine response to E 2 (Xu et al. 1998) .
Mice with altered localization of ERa
A mutated mouse ERa that remains sequestered outside the nucleus (ERaH2NES), is unable to mediate transcriptional responses in a cell based assay, but maintains estrogen induced MAPK phosphorylation (Burns et al. 2011) . Targeting steroid receptors to the membrane involves palmitoylation, which is facilitated by HSP27 (Levin 2011) . The palmitoylation promotes interaction with caveolin-1, which then results in localization of the receptor in membrane caveolin rafts. Two laboratories have mutated the palmitoylation site of the mouse ERa, and created knock in mouse models to study the effect of disabling this mechanism in vivo (Adlanmerini et al. 2014 , Pedram et al. 2014 . Both mouse lines have ovarian defects, but differ in several aspects (Table 2 ). Both involved knocking in an ERa with the same mutation of cysteine 451 to alanine. The first, C451A-ERa, exhibits normal uterine development and E 2 induced growth response (Adlanmerini et al. 2014) , whereas the nuclearonly ERa (NOER) has a hypoplastic ERa-null like uterus that fails to respond to E 2 (Pedram et al. 2014 ). Both models have elevation in LH, but only the NOER has elevated E 2 . These mixed results remain to be reconciled to definitively illustrate the role of membrane associated ERa in these physiological systems.
Conclusion
Female reproduction is a complex staged series of physiological responses occurring in multiple organ systems activated by estrogen and estrogen receptors. Cell based studies have uncovered that cellular signaling mechanisms for ER are multifaceted regarding gene regulation. Because of the complexity with what is known about female reproduction and fertility, the mechanisms and activities cannot be clearly studied or tested in cell based systems. The development of gene targeting has allowed the evaluation of the physiological roles of estrogen action and ER functionality under natural biological conditions. It is now apparent from the experimental and clinical reports outlined in this review that the primary mediator of female reproduction is ERa. What functional aspects of the ERa action are required will be forthcoming with the continued use of new technologies and experimental approaches, which will lead to a better understanding for the potential origins of infertility, reproductive tract disease and development of reproductive therapeutics.
